Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Vor BioPharma Inc (VOR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$20.12+1.31%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for VOR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Secure funding through private placements | This funding supports its cell therapy development through mid-2028. | Intact | failure to raise at least $75 million in any quarter if cash runway threatened | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, early-stage biotechnology business, not a proven earnings compounder. The thesis is on watch: recent financial performance is weak, management execution is rated volatile, and the evidence snapshot has low overall confidence.
The evidence gives no valuation level or clear account of what investors expect, so whether VOR is cheap, fair, or expensive versus peers cannot be assessed. The snapshot describes limited fragility from weak execution and a turbulent sector, but does not show that the full combination of expensive valuation, weak execution, and sector pressure is priced in.
Near term, losses and uncertain execution remain central: VOR reported a net loss of $62.8 million in 2026-Q2, and the evidence flags erratic earnings results and a 45% chance of a miss. Over the multi-year view, telitacicept’s global Phase 3 development and China’s conditional approval are progress, but no revenue or operating income data show financial delivery yet; stated cash runway extends into mid-2028.
A meaningful negative scenario is a guidance cut at the next call; weakening job growth could also add pressure across cyclical and healthcare names. A more favorable sector backdrop depends in part on healthcare bellwethers continuing to report strong results and raise guidance, while VOR’s longer-term case hinges on development, regulatory progress, and eventual commercial execution translating into measurable financial results.
Over the next one to three years, VOR remains a high-risk, early-stage thesis with important clinical and regulatory progress but no demonstrated financial delivery. The evidence supports watching execution, losses, and runway closely, while confidence in the assessment remains low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Vor BioPharma Inc's published investment case. The stated target is >= $450 million cash and equivalents. |
| Intact |
| cash falls below $300 million before mid-2028 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage operating losses to preserve cash | A supporting condition in Vor BioPharma Inc's published investment case. The stated target is Limit quarterly operating loss to less than $40 million. | Intact | quarterly operating loss exceeds $50 million persistently | Operating income: $-58.444M FY2026-Q3; GAAP. Published target: Limit quarterly operating loss to less than $40 million. Target period is not explicitly aligned with this observation. Oct 30, 2026-58,444,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.48 → $-3.93 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-07-25 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-07-26 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-07-27 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-07-28 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-07-29 | $-3.74 | $0 | 5 / 8 |
| 2026-07-30 | $-3.74 | $0 | 5 / 8 |
| 2026-07-31 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-01 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-02 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-03 | $-3.74 | $0 | 5 / 8 |
| 2026-08-04 | $-3.74 | $0 | 5 / 8 |
| 2026-08-05 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-06 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-08 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-09 | $-3.74 | $0 | 5 / 8 |
| 2026-08-10 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-12 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-13 | $-3.74 | $0 | 5 / 8 |
| 2026-08-14 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-15 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-16 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-17 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-18 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-19 | $-3.48 | $10,000,000 | 6 / 8 |
| 2026-08-20 | $-3.60 | $10,000,000 | 6 / 8 |
| 2026-08-21 | $-3.60 | $10,000,000 | 6 / 8 |
| 2026-08-22 | $-3.60 | $10,000,000 | 6 / 8 |
| 2026-08-23 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-08-24 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-08-25 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-08-26 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-08-27 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-08-28 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-08-29 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-08-30 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-08-31 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-01 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-02 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-03 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-04 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-05 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-06 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-07 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-08 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-09 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-10 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-11 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-12 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-13 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-14 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-15 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-16 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-17 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-18 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-19 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-20 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-21 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-22 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-23 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-24 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-25 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-26 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-27 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-28 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-29 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-09-30 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-01 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-02 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-03 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-04 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-05 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-06 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-07 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-08 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-09 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-10 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-11 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-12 | $-3.60 | $10,000,000 | 6 / 9 |
| 2026-10-13 | $-3.60 | $10,000,000 | 5 / 9 |
| 2026-10-14 | $-3.60 | $10,000,000 | 5 / 9 |
| 2026-10-15 | $-3.60 | $10,000,000 | 5 / 9 |
| 2026-10-16 | $-3.65 | $10,000,000 | 5 / 9 |
| 2026-10-17 | $-3.65 | $10,000,000 | 5 / 9 |
| 2026-10-18 | $-3.65 | $10,000,000 | 5 / 9 |
| 2026-10-19 | $-3.65 | $10,000,000 | 5 / 9 |
| 2026-10-20 | $-3.65 | $10,000,000 | 5 / 9 |
| 2026-10-21 | $-3.65 | $10,000,000 | 5 / 9 |
| 2026-10-22 | $-3.64 | $10,000,000 | 6 / 10 |
| 2026-10-23 | $-3.64 | $10,000,000 | 6 / 10 |
| 2026-10-24 | $-3.64 | $10,000,000 | 6 / 10 |
| 2026-10-25 | $-3.64 | $10,000,000 | 6 / 10 |
| 2026-10-26 | $-3.64 | $10,000,000 | 6 / 10 |
| 2026-10-27 | $-3.64 | $10,000,000 | 6 / 10 |
| 2026-10-28 | $-3.64 | $10,000,000 | 6 / 10 |
| 2026-10-29 | $-3.64 | $10,000,000 | 6 / 10 |
| 2026-10-30 | $-3.64 | $10,000,000 | 6 / 10 |
| 2026-10-31 | $-3.86 | $10,000,000 | 6 / 10 |
| 2026-11-01 | $-3.86 | $10,000,000 | 6 / 10 |
| 2026-11-02 | $-3.86 | $10,000,000 | 6 / 10 |
| 2026-11-03 | $-3.93 | $10,000,000 | 6 / 10 |
| 2026-11-04 | $-3.93 | $10,000,000 | 6 / 10 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.